Anti-Glomerular Basement Membrane (Anti-GBM) Disease - Epidemiology Forecast to 2030

DelveInsight’s "Anti-Glomerular Basement Membrane (Anti-GBM) Disease - Epidemiology Forecast-2032" report delivers an in-depth understanding of the disease, historical and forecasted Anti-GBM Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Anti-GBM Disease Understanding
Anti-Glomerular Basement Membrane (anti-GBM) disease (also known as Goodpasture syndrome or disease) is a rare but serious autoimmune disease that causes inflammation in the kidneys and lungs. Anti-GBM disease may affect only the kidneys; however, when it causes both kidney and lung disease, it is called Goodpasture’s syndrome. In anti-GBM disease, the immune system mistakenly makes “anti-GBM antibodies” that attack the lungs and kidneys, leading to bleeding and inflammation in the organs. It is also characterized by the inflammation of the filtering structures (glomeruli) of the kidneys (glomerulonephritis) and excessive bleeding into the lungs (pulmonary hemorrhaging). Autoimmune syndromes occur when the body’s natural defense systems (antibodies) against invading or foreign organisms begin to attack the body’s tissue for unknown reasons.
Anti-GBM disease can affect just the kidneys or both the lungs and kidneys (it is uncommon for only the lungs to be affected). These organs are affected because the basement membrane that is targeted or attacked in this disease is only accessible to antibodies in the kidneys and lungs (not in other organs).
The anti-GBM is the most specific term and refers to the presence of renal and pulmonary involvement, along with anti-glomerular basement membrane antibodies. The spectrum of the disease may present classically or glomerulonephritis alone. In anti-GBM disease, the body creates autoantibodies that recognize and attach to the basement membrane, which is a part of the wall of capillary blood vessels in the kidneys and lungs. Once the autoantibodies attach to the basement membrane, this creates a signal to the body’s immune system to attack.
Anti-GBM Disease Diagnosis
Patients are tested for serum anti-GBM antibodies by indirect immunofluorescence testing or, when available, direct enzyme-linked immunosorbent assay (ELISA) with recombinant or human NC-1 alpha3. The presence of these antibodies confirms the diagnosis. Anti-neutrophil cytoplasmic antibodies (ANCA) testing is seen to be positive (in a peripheral pattern) only in 25% of patients with Goodpasture syndrome.
Anti-GBM antibodies can be tested with different diagnostic methods including Physical examination, anti-GBM antibody testing, Anti-neutrophil cytoplasmic antibody (ANCA) testing, renal biopsy, alveolar hemorrhage, and chest radiograph. In patients with evidence of diffuse alveolar hemorrhage and renal involvement, kidney biopsy is considered to identify the underlying cause and help direct therapy. Percutaneous kidney biopsy is the preferred invasive procedure to prove the diagnosis of anti-GBM disease. Renal biopsy provides a comparatively higher yield than lung biopsy, but transbronchial or open lung biopsy may be performed in cases where a renal biopsy cannot be performed. The biopsy tissue must also be processed for light microscopy, immunofluorescence, and electron microscopy.
Epidemiology Perspective by DelveInsight
The anti-GBM epidemiology division provides insights about historical and current Anti-GBM Disease patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
In the year 2020, the total incident cases of Anti-GBM Disease was 1,117 cases in the 7MM which are expected to grow during the study period, i.e., 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted anti-GBM epidemiology segmented as Total Incident Cases of Anti-GBM Disease in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country Wise- Anti-GBM Disease Epidemiology
Estimates show that the highest cases of Anti-GBM Disease in the 7MM were in United States, followed by the Germany, France, the United Kingdom, Italy, Spain, and Japan in 2020.
In the United States, the total number of incident cases of Anti-GBM Disease was 532 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
 In the year 2020, the total incident cases of Anti-GBM Disease were 522 cases in EU-5 which are expected to grow during the study period, i.e., 2018–2030.
 In Japan, the total number of incident cases of Anti-GBM Disease was 63 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
Scope of the Report
• The Anti-GBM Disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Anti-GBM Disease Report and Model provide an overview of the risk factors and global trends Anti-GBM Disease in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of Anti-GBM Disease in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Anti-GBM Disease.
• The report provides the segmentation of the Anti-GBM Disease epidemiology by total incident cases in the 7MM.
Report Highlights
• 10-Year Forecast of Anti-GBM Disease epidemiology
• 7MM Coverage
• Total incident Cases of Anti-GBM Disease
KOL-Views
We interview KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population of Anti-GBM?
• What are the key findings of the Anti-GBM epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018–2030)?
• What would be the total number of patients of Anti-GBM across the 7MM during the study period (2018–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Anti-GBM?
Reasons to buy
The Anti-GBM Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Anti-GBM market
• Quantify patient populations in the global Anti-GBM market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Anti-GBM therapeutics in each of the markets covered
• Understand the magnitude of Anti-GBM population by its age group-specificity
• The Anti-GBM epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Anti-GBM Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2018–2030